Fentanyl Citrate

Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development. ORLANDO, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has selected the commercial worldwide brand name candidate for its lead product, an abuse deterrent fentanyl transdermal system. The proposed brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval. In addition, the selected name is being submitted to the United States Patent and Trademark Office for trademark registration and to secure full intellectual property rights in the United States and internationally. The company engaged Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development services to develop the worldwide commercial brand name and visual identity for the product. This product utilizes Nutriband’s AVERSA™ abuse deterrent transdermal technology and has the potential to be the world’s first abuse-deterrent patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl. Nutriband’s abuse deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and the product is in development for all major medical markets worldwide. Developing a proprietary brand name for a prescription drug product is a critical element in drug product development because the end users (doctors, pharmacists, patients) must be able to easily distinguish a proprietary name from other drug names that are phonetically similar (sound-alike names) or similar in their spelling or appearance (look-alike names). In addition, if the drug name is otherwise confusing or misleading, the patient might receive the wrong product and the subsequent medication error could lead to significant harm to the patient. Brand Institute has been leading the market for over 20 years with a 75% share of drug name approvals globally, including 87% of FDA approved names in 2024. In addition, Brand Institute has been responsible for many of the opioid chronic pain product brand names and specifically a majority of the abuse deterrent opioid product brand names approved by FDA for sale in the United States. Drug Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, will provide regulatory services, solutions and support on the project. DSI is led by former officials from US Food & Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), United States Adopted Name Council (USAN), and World Health Organization (WHO) who co-authored the naming guidance documents while with their former respective agencies. Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. 1 Health Advances Aversa Fentanyl market analysis report 2022 Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release. Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 5,000 marketed healthcare brand names and 1,800 USAN/INN nonproprietary names for nearly 1,600 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year with healthcare manufacturers. Drug Safety Institute is composed of former naming regulatory officials from global government health agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association (AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their former respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications to ensure safety and prevent medication errors. To learn more about Brand Institute's capabilities and experience, please visit www.brandinstitute.com and contact your local Brand Institute representative. Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof. Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc. Brand Institute and Drug Safety Institute are registered trademarks of Brand Institute, Inc.

Uppsala, Sweden – March 24, 2026 – Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) today welcomes investors, analysts and media to attend the company’s R&D Day. The event starts at 9.30 am CET, with registration from 9.00 am, and takes place at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden. With more than 30 years of experience in drug delivery and multiple products approved globally, Orexo has built a strong scientific heritage. Following the divestment of Zubsolv® in the US, the company has entered a new era as a focused drug delivery company, with the ambition to achieve global leadership in the development of amorphous formulations and to advance powder‑based pharmaceutical development programs across multiple routes of administration. At the core of this strategy is AmorphOX®, a next‑generation platform that enhances bioavailability and stability for both small and large molecules (incl. peptides and vaccine) and enables new approaches to route of administration, manufacturing, and distribution. During the day, CEO Nikolaj Sørensen and the management team will provide deeper insights into Orexo’s updated strategy and development priorities, including the company’s innovation capabilities, pipeline, and manufacturing expertise. Presentation materials will be made available on the company’s website when the program starts. A recorded version of all presentations will be published on the website no later than the day after the event. Agenda for the day see below, and on the R&D Day webpage: https://orexo.com/investors/calendar/2026-03-24-orexo-rd-day-2026/. Time am CETTopic or activityPresenter9:00 – 9.30Registration and coffee. 9:30 – 9:45 Shaping Orexo’s future: Strategic priorities and value creation.Nikolaj Sørensen, President and CEO. 9:45 – 10:00 AmorphOX: A unique opportunity to transform drug delivery of biomolecules in an established scalable commercial supply chain.Robert Rönn, SVP Head of R&D / Cecilia Coupland, SVP Head of Operations. 10:00 – 10:15 AmorphOX: Moving beyond nasal delivery in GLP-1s and expanding into new areas with significant market needs through preclinical innovation, and strategic partnerships.Lisa Moore, SVP Product and Portfolio Strategy / Robert Rönn10:15-10:30OX640: Advancing a best‑in‑class nasal epinephrine product with improved stability, bioavailability, and patient convenience, supported by accelerated development and scalable manufacturing.Lisa Moore / Cecilia Coupland10:30-10:45Break. 10:45-11:00OX390: Developing the world’s first medical countermeasure (MCM) to the rising threat from xylazine and medetomidine in collaboration with BARDA, a center within the US Department of Health and Human Services.Edward Kim, Chief Medical Officer. 11:00-11:15Expert perspectives: Why counter-measures are needed for the emerging threats from xylazine, medetomidine, and fentanyl combinations.Mark A. Smith, PhD Davidson College, NC, US. Dr Smith will attend through a prerecorded video.11:15-11:30Building a viable business model through business development.Fredrik Järrsten, EVP and CFO, Head of Business Development. 11:30-12:00Q&A, incl closing remarks by CEO.All presenters.12 pmLunch & networking. Notes: OX640 is a powder-based intranasal epinephrine product candidate in development for the emergency treatment of Type I allergic reactions; OX390 is a powder-based intranasal rescue medication candidate in development for adulterated overdoses. Neither product has been approved by any regulatory agency. For further information Lena Wange, IR and Communications Director Tel: +46 (0)18 780 88 00 Email: ir@orexo.com About Orexo Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States. For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube. The information was submitted for publication at 7.30 am CET, on March 24, 2026.